Information Library

Lower portfolio & investment risks

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • Managing Pharmacovigilance as a Business

    July 28, 2010
    The three steps required to develop a strategic approach to global capacity management.

  • Capital - sharing risks, expanding opportunities

    July 14, 2010
    This Capital brochure reviews how Quintiles helps biopharma allies maximize the value of assets, reduce risk, accelerate outcomes and increase rewards.

  • Vital Insights

    June 8, 2010
    Quintiles conducted an exhaustive analysis into global and U.S. responses to the use of comparative effectiveness research, identifying key signals to help the customer recognize risk scenarios.

  • Translational R&D Services Fact Sheet

    April 5, 2010
    Quintiles’ Translational R&D Center of Excellence performs groundbreaking research and offers novel findings in oncology for biopharmaceutical companies. Quintiles provides a range of laboratory, clinical and capital solutions to help maximize the success of oncology R&D programs. Through translational research, Quintiles seeks to improve the success of drug development programs and to benefit patients by providing customers with a better understanding of therapeutic targets, molecular signaling, drug biology and patient response.

  • QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT

    September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®.

  • Rebalancing Risk to Transform R&D

    June 3, 2009
    A strategic approach to re-balancing the main components of biopharma company risk: portfolio, operational and resource.

  • James C. Kirk

    March 25, 2009
    Jim joined Eidetics in 1988 from senior management positions in consumer and industrial product marketing, strategy, and development positions at Ocean Spray Cranberries and Gillette Company. Previously at Ocean Spray, Jim successfully spearheaded the company’s new Ingredient Division.

  • Adrian McKemey, Ph.D.

    March 25, 2009
    Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting.

  • Jim Featherstone, Ph.D.

    March 25, 2009
    Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

  • Jay Norman

    March 24, 2009
    President – Quintiles Consulting Jay brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer.

Page 1 of 2 (14 results)

Subscribe to Email Based on Your Interests

Set preferences